Clinical Trial Update: A Pilot Study to Characterize the Biological Effect of a Pre-planned 12 Week Dose Interruption of Natalizumab [Phase 4]

View source ↗

Summary

A Phase 4 pilot study evaluating the biological effects of a planned 12-week interruption of natalizumab in patients with relapsing forms of multiple sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Multiple Sclerosis Relapsing-remitting

Drugs mentioned

• Natalizumab (natalizumab)

Snippet

Sponsor: Berkovich, Regina MD, PhD Inc. | Conditions: Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting | Phase 4 | Status: UNKNOWN